Identification of high-risk patients with a seven-biomarker prognostic signature for adjuvant treatment trial recruitment in American Joint Committee on Cancer v8 stage I–IIA cutaneous melanoma
Open Access
- 7 January 2023
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 182, 77-86
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Revisiting determinants of prognosis in cutaneous melanomaCancer, 2015
- Analysis of Melanoma Recurrence Following a Negative Sentinel Lymph Node BiopsyMelanoma Management, 2015
- More People Die from Thin Melanomas (≤1 mm) than from Thick Melanomas (>4 mm) in Queensland, AustraliaJournal of Investigative Dermatology, 2015
- Construction and Analysis of Multiparameter Prognostic Models for Melanoma Outcome2013
- A Seven-Marker Signature and Clinical Outcome in Malignant Melanoma: A Large-Scale Tissue-Microarray Study with Two Independent Patient CohortsPLOS ONE, 2012
- Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and ElaborationPLOS Medicine, 2012
- Biomarkers: The Useful and the Not So Useful—An Assessment of Molecular Prognostic Markers for Cutaneous MelanomaJournal of Investigative Dermatology, 2010
- Use of Archived Specimens in Evaluation of Prognostic and Predictive BiomarkersJNCI: Journal of the National Cancer Institute, 2009
- Tissue Biomarkers for Prognosis in Cutaneous Melanoma: A Systematic Review and Meta-analysisJNCI: Journal of the National Cancer Institute, 2009
- REporting recommendations for tumour MARKer prognostic studies (REMARK)British Journal of Cancer, 2005